Ipamorelin stimulates a short pulse of growth hormone. It is claimed to improve sleep, recovery, muscle gain and fat loss.
What Ipamorelin does and why that matters
Ipamorelin activates a ghrelin-related signal that prompts the pituitary gland to release a short pulse of growth hormone. It is claimed to improve sleep, recovery, muscle and fat loss. Human studies show that growth hormone rises briefly, but they do not establish those everyday benefits or a nightly wellness protocol. [1,2,3]
Function evidence: Human growth-hormone response; sleep and body-composition benefits unproven
What people hope to notice
Ipamorelin is claimed to improve sleep, training recovery, muscle and fat loss. The clearest human finding is narrower: growth hormone rises for a short time after exposure. The volunteer studies did not show better sleep, strength, body composition or injury recovery. A separate placebo-controlled trial tested bowel recovery after surgery and did not find a significant efficacy difference. These results do not support a nightly wellness routine or predict a noticeable physique benefit. [1,2,3]
What supports this description: Human hormone response and a negative clinical trial; claimed wellness outcomes unproven
Ipamorelin Dosing status
Dose: No established routine treatment dose in the cited evidence. | Frequency: No validated routine schedule. | Cycle: No validated cycling schedule. | Route: Research routes do not establish a routine treatment route.
Preparation: No validated patient preparation instructions in these sources..
The cited human trials used intravenous administration. They do not establish nightly subcutaneous dosing, fasting rules, cycling or mixing compatibility with CJC-1295. FDA identifies important safety gaps for other injectable routes. [1,2,4]
Ipamorelin Effects
Growth-hormone response. Healthy male volunteers received infusions in a dose-escalation study. Growth hormone increased, but clinical sleep or physique benefits were not tested. [1]
Postoperative bowel recovery. The placebo-controlled trial enrolled 117 patients; 114 were included in safety and modified intent-to-treat analyses. Its efficacy analyses showed no significant difference between groups. [2]
Hormone selectivity. The early selectivity experiment included swine. It does not establish an absence of cortisol, prolactin or other effects across human doses and routes. [3]
Ipamorelin Side Effects
Serious events and route-specific uncertainty. FDA flags serious events in intravenous research and insufficient safety information for certain other injectable routes. Reliable risk estimates for a routine subcutaneous regimen are not established. [4,5]
Immune-response and product-quality concerns. FDA identifies potential immune-response risks related to peptide aggregation or impurities in compounded ipamorelin acetate. [4]
Frequently Asked Questions About Ipamorelin
Does ipamorelin improve sleep or build muscle?
The cited human studies measured hormone responses or recovery of bowel function after surgery. They do not establish those uses. [1,2]
Is it proven to affect only growth hormone?
No. The often-cited early selectivity findings came from animal experiments. They cannot establish that all other human hormone levels and clinical outcomes are unaffected. [3]
Is there an established bedtime dose or fasting window?
The cited human trials do not validate a routine bedtime subcutaneous schedule, food-timing rule or cycling interval. [1,2]
Can it be mixed with CJC-1295?
These trials did not establish the efficacy, safety or syringe compatibility of that combination. [1,2]
Were serious adverse events reported?
FDA notes serious events, including deaths, in intravenous postoperative research. Its advisory assessment says the relationship of the deaths to ipamorelin is unclear. This is neither proof that the drug caused them nor evidence that other routes are safe. [4,5]
Evidence
Limited human studies; routine benefit unestablished. A healthy-volunteer infusion study measured growth-hormone responses. A postoperative randomized trial found no significant efficacy difference from placebo. These findings do not establish sleep, recovery or body-composition benefits. [1,2]
Approval status: Investigational use in the cited studies. [1,2]
References
Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 1999. PMID 10496658
Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 2014. PMID 25331030
Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. PMID 9849822
U.S. Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks , 2026. Source
U.S. Food and Drug Administration October 29, 2024 Pharmacy Compounding Advisory Committee presentations: ipamorelin safety assessment , 2024. Source
Storage
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
